The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2022 | ERMES: FOLFIRI/cetuximab followed by cetuximab inferior to SOC in RAS & BRAF wt mCRC
Armando Orlandi, MD, PhD, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy, provides an overview of the Phase III ERMES study (NCT02484833), which assessed first-line FOLFIRI and cetuximab with or without additional cetuximab alone in patients with RAS and BRAF wild-type metastatic colorectal cancer (mCRC). Non-inferior progression-free survival and a lower incidence of grade 3 and 4 adverse incidents were the primary endpoints, which were not met in this trial in the cohort receiving additional cetuximab. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
